HSD11B2
Basic information
Region (hg38): 16:67430652-67437553
Links
Phenotypes
GenCC
Source:
- apparent mineralocorticoid excess (Strong), mode of inheritance: AR
- apparent mineralocorticoid excess (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Cortisol 11-beta-ketoreductase deficiency | AR | Renal | There is a broad range of severity, including potentially lethal early chidlhood disease, and medical treatment (eg, with spironolactone) can be beneficial | Endocrine; Renal | 870517; 1740492; 3460996; 3164727; 8370690; 7670488; 9683587; 9707624; 10536001; 10523339; 17314322; 19909806 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (3 variants)
- Apparent mineralocorticoid excess (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HSD11B2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 21 | 25 | ||||
missense | 39 | 48 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 4 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 8 | |||||
Total | 4 | 5 | 40 | 29 | 9 |
Highest pathogenic variant AF is 0.00000669
Variants in HSD11B2
This is a list of pathogenic ClinVar variants found in the HSD11B2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-67430908-G-A | Likely benign (Nov 26, 2019) | |||
16-67430991-G-A | Benign (Nov 24, 2020) | |||
16-67431272-G-A | Likely benign (Mar 31, 2022) | |||
16-67431290-C-G | Benign (May 01, 2023) | |||
16-67431290-C-T | Likely benign (Jan 04, 2024) | |||
16-67431321-C-A | Inborn genetic diseases | Uncertain significance (Sep 07, 2022) | ||
16-67431324-TCA-T | Apparent mineralocorticoid excess | Pathogenic (Apr 01, 2007) | ||
16-67431328-ACCTGCGTCTGGGCCGCCCGCTGCTGGCGGCGCTGGCGCTGCTGGCCGCGCTCGACTGGCTGTGCCAGCGCCTGCTGCCCCCGCCGGCCGCACTCG-A | Pathogenic (Oct 03, 2022) | |||
16-67431347-G-A | Likely benign (Jan 01, 2023) | |||
16-67431372-G-A | Benign (Sep 05, 2022) | |||
16-67431407-CCCGCCGGCCGCACTCGCCGTGCTGGCCG-C | Pathogenic (Aug 04, 2023) | |||
16-67431412-C-T | Inborn genetic diseases | Likely benign (Jan 30, 2024) | ||
16-67431420-C-T | Inborn genetic diseases | Uncertain significance (Jan 10, 2023) | ||
16-67431425-C-A | not specified | Benign/Likely benign (Nov 02, 2023) | ||
16-67431431-G-A | Likely benign (Aug 04, 2023) | |||
16-67431440-C-CGCA | Uncertain significance (Dec 21, 2023) | |||
16-67431458-C-T | Likely benign (Nov 16, 2023) | |||
16-67431468-CGC-GG | Apparent mineralocorticoid excess | Uncertain significance (Dec 30, 2017) | ||
16-67431484-C-G | Inborn genetic diseases | Uncertain significance (Sep 25, 2023) | ||
16-67431484-C-T | Inborn genetic diseases | Uncertain significance (Feb 14, 2023) | ||
16-67435628-G-A | not specified • Apparent mineralocorticoid excess • HSD11B2-related disorder | Conflicting classifications of pathogenicity (Aug 26, 2024) | ||
16-67435634-A-C | Apparent mineralocorticoid excess | Uncertain significance (Apr 20, 2017) | ||
16-67435673-C-G | Inborn genetic diseases | Uncertain significance (Mar 31, 2024) | ||
16-67435680-C-T | Likely benign (Jul 25, 2023) | |||
16-67435698-C-T | Likely benign (Jul 29, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HSD11B2 | protein_coding | protein_coding | ENST00000326152 | 5 | 6902 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.118 | 0.859 | 125723 | 0 | 9 | 125732 | 0.0000358 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.02 | 162 | 203 | 0.798 | 0.0000146 | 2520 |
Missense in Polyphen | 43 | 72.565 | 0.59258 | 1024 | ||
Synonymous | -0.0639 | 89 | 88.2 | 1.01 | 0.00000620 | 929 |
Loss of Function | 1.95 | 3 | 9.47 | 0.317 | 4.14e-7 | 141 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000119 | 0.000119 |
Ashkenazi Jewish | 0.0000999 | 0.0000992 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000445 | 0.0000440 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids.;
- Pathway
- Steroid hormone biosynthesis - Homo sapiens (human);Aldosterone-regulated sodium reabsorption - Homo sapiens (human);Steroidogenesis;Apparent mineralocorticoid excess syndrome;3-Beta-Hydroxysteroid Dehydrogenase Deficiency;21-hydroxylase deficiency (CYP21);Corticosterone methyl oxidase I deficiency (CMO I);Corticosterone methyl oxidase II deficiency - CMO II;Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase Deficiency;Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency;Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;17-alpha-hydroxylase deficiency (CYP17);11-beta-hydroxylase deficiency (CYP11B1);Glucocorticoid and Mineralcorticoid Metabolism;Prostaglandin Synthesis and Regulation;Metabolism of lipids;Androgen and estrogen biosynthesis and metabolism;Metabolism;Metabolism of steroid hormones;Metabolism of steroids;C21-steroid hormone biosynthesis and metabolism;Glucocorticoid biosynthesis;Steroid hormones
(Consensus)
Recessive Scores
- pRec
- 0.644
Intolerance Scores
- loftool
- 0.130
- rvis_EVS
- -0.47
- rvis_percentile_EVS
- 23.25
Haploinsufficiency Scores
- pHI
- 0.726
- hipred
- Y
- hipred_score
- 0.713
- ghis
- 0.467
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.993
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hsd11b2
- Phenotype
- muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; neoplasm; digestive/alimentary phenotype; renal/urinary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);
Gene ontology
- Biological process
- response to hypoxia;regulation of blood volume by renal aldosterone;glucocorticoid biosynthetic process;female pregnancy;response to food;response to insulin;response to drug;response to glucocorticoid;oxidation-reduction process
- Cellular component
- endoplasmic reticulum membrane
- Molecular function
- 11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity;steroid binding;NAD binding